PTPI (Petros Pharmaceuticals) ROE % Adjusted to Book Value: -1,308.46% (As of Mar. 2026)


What is Petros Pharmaceuticals ROE % Adjusted to Book Value?

Petros Pharmaceuticals PTPI -1.07% ROE % Adjusted to Book Value is -1,308.46% as of Mar. 2026.

Petros Pharmaceuticals's ROE % for the quarter that ended in Mar. 2026 was -170.10%. Petros Pharmaceuticals's PB Ratio for the quarter that ended in Mar. 2026 was 0.13. Petros Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -1,308.46%.

Petros Pharmaceuticals ROE % Adjusted to Book Value Related Terms

Petros Pharmaceuticals ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Petros Pharmaceuticals's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Petros Pharmaceuticals ROE % Adjusted to Book Value Chart

Petros Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial -17.47 -264.48 -159.86 0.00 Negative Equity

Petros Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 Negative Equity -314.93 -360.08 -1,308.46

PTPI vs GCAN, KOAN, PNXP: ROE % Adjusted to Book Value Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Petros Pharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Petros Pharmaceuticals ROE % Adjusted to Book Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Petros Pharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Petros Pharmaceuticals's ROE % Adjusted to Book Value falls into.


Petros Pharmaceuticals ROE % Adjusted to Book Value Calculation

Petros Pharmaceuticals's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=Negative Equity / 0.12
=Negative Equity

Petros Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-170.10% / 0.13
=-1,308.46%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -1,308.46% mean?
Petros Pharmaceuticals (PTPI) has a ROE % Adjusted to Book Value of -1,308.46% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Petros Pharmaceuticals and its competitors.
Is Petros Pharmaceuticals' ROE % Adjusted to Book Value too high?
Petros Pharmaceuticals' current ROE % Adjusted to Book Value is -1,308.46%.
How does Petros Pharmaceuticals' ROE % Adjusted to Book Value compare to GCAN and KOAN?
Petros Pharmaceuticals' ROE % Adjusted to Book Value of -1,308.46% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Petros Pharmaceuticals and its competitors. Petros Pharmaceuticals's current ROE % Adjusted to Book Value is -1,308.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Petros Pharmaceuticals stock overvalued right now?
Petros Pharmaceuticals (PTPI) has a current ROE % Adjusted to Book Value of -1,308.46%. The current ROE % Adjusted to Book Value is -1,308.46%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Petros Pharmaceuticals (PTPI), the current ROE % Adjusted to Book Value is -1,308.46% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Petros Pharmaceuticals Business Description

Address 1185 Avenue of the Americas, 3rd Floor, New York, NY, USA, 10036
Petros Pharmaceuticals Inc is a men's health pharmaceutical company. The Company is working towards the goal of becoming an innovator in the emerging self-care market, driving expanded access to key nonprescription pharmaceuticals as Over-the-Counter and nonprescription drug products with additional conditions for nonprescription use (ACNU Products) treatment options. Petros is pursuing the development of a proprietary integrated technology solutions platform containing two components: SaaS, designed to assist pharmaceutical companies in operationalizing and commercializing an Rx-to-OTC switch as an element in the development of an ACNU Product, and a potential Software as a Medical Device component, which guides the consumer in navigating appropriate self-selection or deselection.